Home/Pipeline/VLA2111

VLA2111

Chikungunya (prevention)

Phase 1Active

Key Facts

Indication
Chikungunya (prevention)
Phase
Phase 1
Status
Active
Company

About Valneva SE

Valneva SE is a publicly traded biotech company dedicated to providing life-saving vaccines against infectious diseases. Its strategy combines commercial revenue from its travel and endemic vaccines with a late-stage pipeline targeting Lyme disease and other threats. The company leverages its proprietary vaccine platform technology and in-house manufacturing to control the entire value chain, positioning itself as a key player in the global response to emerging infectious diseases and neglected travel health markets.

View full company profile